Yes, but initial discovery of molecules and novel mechanisms is massive. That was the last generational change in modern drug research was the movement to high throughput screening, going from the ability to screen 10's of molecules to hundreds of thousands to find 'hits'. Better and more focused models, especially ones trained internally at big pharma companies will accelerate that portion of the pipeline, or increase the hit rate of successful compounds. Several companies are already taking this approach like Novo has been. There are other more early stage companies like Recursion and others that are doing the same thing. They are more tech companies than traditional wet lab companies.